Skip to main content
. 2011 Nov 25;18(1):87. doi: 10.1186/1423-0127-18-87

Figure 7.

Figure 7

Therapeutic effects of primary MSCs and IMSCs in rat model of neonatal HIBD by cell transplantation. A: In hidden platform tests (from D2 to D5), the escape latency of PBS group (*, p < 0.01, PBS vs. control) became shorter after primary MSCs or IMSCs therapy (&, p < 0.05, MSCs/IMSCs vs. PBS). There were no statistical difference between primary MSCs group and IMSCs group (p > 0.05). B: In hidden platform tests (from D2 to D5), the path lengths of PBS group (*, p < 0.01, PBS vs. control) became shorter after primary MSCs or IMSCs therapy (&, p < 0.05, MSCs/IMSCs vs. PBS). There were no statistical difference between primary MSCs group and IMSCs group (p > 0.05). C: In the probe trial on the sixth day, the passing times of PBS group (*, P < 0.01, PBS vs. control) significantly increased after primary MSCs or IMSCs therapy (&, P < 0.05, MSCs/IMSCs vs. PBS). And the MSCs group and IMSCs group had similar passing times (P > 0.05). D: The active avoidance response rate (AARR) of the MSCs group and IMSCs group were significantly higher than that of PBS group on the 3rd, 4th and 5th test day (&, P < 0.05, MSCs/IMSCs vs. PBS). E: The no avoidance response rate (NARR) of MSCs group and IMSCs group were significantly lower than that of PBS group on the 2nd and 3rd test day (&, P < 0.05, MSCs/IMSCs vs. PBS).